- Agreement establishes direct distribution channel for customers in Japan, providing local support and expertise
- Partnership solidifies CN Bio’s presence in Asian markets and supports ongoing global expansion
Cambridge, UK, 14 January 2025: CN Bio, a leading provider of Organ-on-a-chip (OOC) systems and solutions that accelerate drug discovery and development workflows, announces it has entered into a strategic partnership with Japanese life sciences research equipment distributor, Primetech. In response to rapidly growing demand for the Company’s OOC solutions, the agreement establishes a new regional distribution network in Japan, providing customers streamlined access to localized support and technical expertise, and solidifies CN Bio’s presence in this key market.
Global legislative changes and localized drives have influenced the growing demand in Japan for new approach methodologies (NAMs). As a result, the country’s OOC market is expanding rapidly; predicted to reach a value of $28.2M by 2030 (CAGR 30.7%)1. Pharmaceutical and biotech companies are recognizing the potential of these approaches to improve preclinical efficacy and safety data generation in drug discovery and development workflows, leading to reduced failure rates of new drug candidates. CN Bio has strategically partnered with Primetech Corp. to strengthen its presence in the Asia-Pacific region, expanding direct sales and product support for the Company’s range of industry-leading PhysioMimix® OOC Systems and solutions to existing and new customers.
CN Bio’s benchtop PhysioMimix OOC range accurately mimics human physiology in the laboratory. Using advanced in vitro human organ models, these systems enable more accurate predictions of human drug responses to support the development of novel therapeutics with increased efficiency, whilst relieving the dependence on animal models. These models provide insights into crucial aspects of preclinical drug development, including drug bioavailability, toxicology and disease modelling, providing information on how drugs will perform in patients and reduce the risk of costly late-stage failures in the clinic.
Ryosuke Ogihara, CEO, Primetech Corporation, said: “We are pleased to announce the commencement of our partnership with CN Bio to offer the Company’s range of microphysiological systems and reagents. This innovative technology opens new possibilities in the field of drug discovery and development, and can significantly accelerate the discovery process. Our company is committed to providing cutting-edge solutions to drive our customers' success, and we are confident that CN Bio’s products and expertise will greatly enhance their research efficiency.”
“Partnering with an established distributor like Primetech marks a crucial milestone in our strategy for long-term global growth. Through this, we are solidifying our distribution network in Asia, allowing us to offer our ground-breaking OOC solutions in this region and meet rapidly growing market demand.” said Dr Paul Brooks, CEO, CN Bio:“This agreement will allow us to provide specialized local support to our Japanese customers, and underpins our ongoing commitment to being an international provider of gold-standard OOC solutions, revolutionizing drug discovery on a global scale.”
